

B cells are associated with survival and immunotherapy

Nature

577, 556-560

DOI: [10.1038/s41586-019-1906-8](https://doi.org/10.1038/s41586-019-1906-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Body mass index-associated molecular characteristics involved in tumor immune and metabolic pathways. <i>Cancer & Metabolism</i> , 2020, 8, 21.	2.4	4
2	Sarcoma treatment in the era of molecular medicine. <i>EMBO Molecular Medicine</i> , 2020, 12, e11131.	3.3	154
3	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
4	Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. , 2020, 8, e001287.		24
6	Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. <i>Cancer Treatment Reviews</i> , 2020, 91, 102115.	3.4	48
7	Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation. <i>Immuno-Oncology Technology</i> , 2020, 7, 15-22.	0.2	3
8	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020, 183, 347-362.e24.	13.5	349
9	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	15.2	193
10	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. <i>Seminars in Immunology</i> , 2020, 48, 101410.	2.7	81
11	Neutrophil diversity and plasticity in tumour progression and therapy. <i>Nature Reviews Cancer</i> , 2020, 20, 485-503.	12.8	548
12	Immune-mediated approaches against COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 630-645.	15.6	260
13	A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 1873.	1.7	40
14	The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease. <i>Cell</i> , 2020, 182, 270-296.	13.5	352
15	Defining HPV-specific B cell responses in patients with head and neck cancer. <i>Nature</i> , 2021, 597, 274-278.	13.7	122
16	Humoral immune responses: Unsung heroes of the war on cancer. <i>Seminars in Immunology</i> , 2020, 49, 101419.	2.7	11
17	Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 249.	3.5	56
18	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. <i>Cancers</i> , 2020, 12, 3392.	1.7	5
19	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85

#	ARTICLE	IF	CITATIONS
20	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. <i>Cell Reports Medicine</i> , 2020, 1, 100139.	3.3	45
21	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020, 48, 101406.	2.7	44
22	MIF-Dependent Control of Tumor Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 609948.	2.2	59
23	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
24	High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. <i>EBioMedicine</i> , 2020, 62, 103131.	2.7	32
25	Protocol for Single-Cell Analysis of Tumor-Infiltrating B Cells Isolated from Human Breast Cancer Tissue Before and After Neo-adjuvant Chemotherapy. <i>STAR Protocols</i> , 2020, 1, 100040.	0.5	3
26	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. <i>Molecular Therapy</i> , 2020, 28, 2367-2378.	3.7	32
27	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , 2020, 20, 662-680.	12.8	860
28	Cell and tissue engineering in lymph nodes for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 42-62.	6.6	43
29	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. <i>Cell</i> , 2020, 182, 1341-1359.e19.	13.5	464
30	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1083-1100.	1.0	27
31	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. <i>Genome Biology</i> , 2020, 21, 263.	3.8	15
32	Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 564714.	1.3	8
33	The Immune Phenotype of Isolated Lymphoid Structures in Non-Tumorous Colon Mucosa Encrypts the Information on Pathobiology of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3117.	1.7	7
34	Chemokine biology on immune checkpoint-targeted therapies. <i>European Journal of Cancer</i> , 2020, 137, 260-271.	1.3	13
35	Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma. <i>BMC Cancer</i> , 2020, 20, 1035.	1.1	6
36	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28960-28970.	3.3	150
37	Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers. <i>Cancers</i> , 2020, 12, 2946.	1.7	6

#	ARTICLE	IF	CITATIONS
38	<p>Cervical Cancer: Emerging Immune Landscape and Treatment</p>. OncoTargets and Therapy, 2020, Volume 13, 8037-8047.	1.0	32
39	CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 6051-6063.	3.2	14
40	Comprehensive profiling of immune-related genes in soft tissue sarcoma patients. Journal of Translational Medicine, 2020, 18, 337.	1.8	18
41	Immunological Network in Head and Neck Squamous Cell Carcinoma"A Prognostic Tool Beyond HPV Status. Frontiers in Oncology, 2020, 10, 1701.	1.3	18
42	Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	7.7	203
43	Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. Nature Communications, 2020, 11, 4861.	5.8	57
44	Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.	3.2	10
45	Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. Cancer Immunology Research, 2020, 8, 1496-1507.	1.6	11
46	Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition. Trends in Immunology, 2020, 41, 948-963.	2.9	41
47	B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors. Cancers, 2020, 12, 2644.	1.7	38
48	New technology on the horizon: Fast analytical screening technique FNA (FAST&FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. Cancer Cytopathology, 2020, 128, 782-791.	1.4	6
49	Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. OncoImmunology, 2020, 9, 1792036.	2.1	31
50	Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy. Cancers, 2020, 12, 2418.	1.7	17
51	Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. International Journal of Oral Science, 2020, 12, 24.	3.6	67
52	Circulation of gut-preactivated na \tilde{v} e CD8 ⁺ T cells enhances antitumor immunity in B cell-defective mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23674-23683.	3.3	22
53	A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. , 2020, 8, e001187.		23
54	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Molecular Cancer, 2020, 19, 141.	7.9	141
55	The Study of Sarcoma Microenvironment Heterogeneity Associated With Prognosis Based on an Immunogenomic Landscape Analysis. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1003.	2.0	17

#	ARTICLE	IF	CITATIONS
56	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. <i>Nature Communications</i> , 2020, 11, 6410.	5.8	66
57	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. <i>Frontiers in Immunology</i> , 2020, 11, 600886.	2.2	43
58	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020, 9, 57.	1.2	58
59	T cell factor 1: A master regulator of the T cell response in disease. <i>Science Immunology</i> , 2020, 5, .	5.6	85
60	Single-Cell RNA-Seq Analysis Reveals Microenvironmental Infiltration of Plasma Cells and Hepatocytic Prognostic Markers in HCC With Cirrhosis. <i>Frontiers in Oncology</i> , 2020, 10, 596318.	1.3	46
61	Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1338-1345.	1.6	44
62	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 393-394.	12.5	9
63	Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 970-985.	2.8	49
64	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 89.	3.5	157
65	PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. <i>Journal of Hematology and Oncology</i> , 2020, 13, 55.	6.9	47
66	The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. <i>Clinical Cancer Research</i> , 2020, 26, 4018-4030.	3.2	44
67	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
68	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 214.	1.8	23
69	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339
70	Immunotherapy in sarcoma: combinations or single agents? In whom?. <i>Current Opinion in Oncology</i> , 2020, 32, 339-343.	1.1	4
71	<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	82
72	Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4346.	1.8	32
73	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15

#	ARTICLE	IF	CITATIONS
74	Impact of multiple hits with cognate antigen on memory CD8+ T-cell fate. <i>International Immunology</i> , 2020, 32, 571-581.	1.8	2
75	Circular RNA and tumor microenvironment. <i>Cancer Cell International</i> , 2020, 20, 211.	1.8	22
76	Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 348.	2.0	4
77	The liver as an immunological barrier redefined by single-cell analysis. <i>Immunology</i> , 2020, 160, 157-170.	2.0	28
78	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
79	Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1779.	1.8	18
80	Lymph node stromal cells: cartographers of the immune system. <i>Nature Immunology</i> , 2020, 21, 369-380.	7.0	198
81	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359.	3.2	117
82	Human Vaccines & Immunotherapeutics: news. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 478-479.	1.4	0
83	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	12.5	189
84	Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 360-369.	0.6	5
85	Molecular pathology of Lynch syndrome. <i>Journal of Pathology</i> , 2020, 250, 518-531.	2.1	96
86	Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. <i>Cancer Letters</i> , 2020, 478, 56-69.	3.2	32
87	Chemotherapy Induces Cancer-Fighting B Cells. <i>Cell</i> , 2020, 180, 1037-1039.	13.5	11
88	Tumor-derived extracellular vesicles: Regulators of tumor microenvironment and the enlightenment in tumor therapy. <i>Pharmacological Research</i> , 2020, 159, 105041.	3.1	16
89	Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 5801-5808.	3.2	26
90	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. <i>Cellular and Molecular Immunology</i> , 2020, 17, 807-821.	4.8	1,136
91	CXCL13-producing PD-1 ^{hi} CXCR5 ^{hi} helper T cells in chronic inflammation. <i>Immunological Medicine</i> , 2020, 43, 156-160.	1.4	13

#	ARTICLE	IF	CITATIONS
92	The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 389-398.	2.5	5
93	The High Level of Tertiary Lymphoid Structure Is Correlated With Superior Survival in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 980.	1.3	17
94	B cells and TLSs facilitate a response to ICI. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 195-195.	12.5	14
95	New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. <i>Nature</i> , 2020, 577, 474-476.	13.7	112
96	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020, 577, 561-565.	13.7	1,209
97	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
98	B cells, plasma cells and antibody repertoires in the tumour microenvironment. <i>Nature Reviews Immunology</i> , 2020, 20, 294-307.	10.6	363
99	Gut-resident CX3CR1 ^{hi} macrophages induce tertiary lymphoid structures and IgA response in situ. <i>Science Immunology</i> , 2020, 5, .	5.6	63
100	Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy. <i>Cancers</i> , 2020, 12, 852.	1.7	19
101	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. <i>Cancers</i> , 2020, 12, 915.	1.7	1
102	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1353-1362.	2.0	34
103	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. <i>Nature Cancer</i> , 2020, 1, 452-468.	5.7	103
104	The emerging role of T follicular helper (TFH) cells in aging: Influence on the immune frailty. <i>Ageing Research Reviews</i> , 2020, 61, 101071.	5.0	36
105	Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. <i>Molecular Carcinogenesis</i> , 2020, 59, 807-821.	1.3	32
106	Correlative Analyses of the SARCO28 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 1258-1266.	3.2	115
107	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
108	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. <i>Seminars in Cancer Biology</i> , 2021, 70, 11-23.	4.3	26
109	High Endothelial Venules Accelerate Naive T _H Cell Recruitment by Tumor Necrosis Factor-Mediated R-Ras Upregulation. <i>American Journal of Pathology</i> , 2021, 191, 396-414.	1.9	8

#	ARTICLE	IF	CITATIONS
110	Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. <i>Hepatology</i> , 2021, 73, 821-832.	3.6	25
111	Calreticulin and cancer. <i>Cell Research</i> , 2021, 31, 5-16.	5.7	174
112	Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses. <i>Gene</i> , 2021, 764, 145105.	1.0	8
113	Prognostic and predictive value of a mRNA signature in peripheral T-cell lymphomas: A mRNA expression analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 84-95.	1.6	9
114	The emerging role of immunotherapy for the treatment of sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 730-738.	0.8	16
115	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
116	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <i>Cancer Cell</i> , 2021, 39, 38-53.e7.	7.7	65
117	Emerging immunotherapies for metastasis. <i>British Journal of Cancer</i> , 2021, 124, 37-48.	2.9	32
118	Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?. <i>Immunotherapy</i> , 2021, 13, 91-93.	1.0	1
119	The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. <i>European Journal of Cancer</i> , 2021, 144, 123-150.	1.3	85
120	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1935-1939.	1.4	8
121	Activation of 4-1BBL+ B cells with CD40 agonism and IFN γ elicits potent immunity against glioblastoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	42
122	Regulatory B cells and T cell Regulation in Cancer. <i>Journal of Molecular Biology</i> , 2021, 433, 166685.	2.0	43
123	Regulation of neuroinflammation by B cells and plasma cells. <i>Immunological Reviews</i> , 2021, 299, 45-60.	2.8	19
124	T-cell infiltration profile in musculoskeletal tumors. <i>Journal of Orthopaedic Research</i> , 2021, 39, 536-542.	1.2	6
125	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
126	The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 853-865.	2.4	8
127	Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 523-527.	4.8	93

#	ARTICLE	IF	CITATIONS
128	Exosomes as mediators of immune regulation and immunotherapy in cancer. <i>FEBS Journal</i> , 2021, 288, 10-35.	2.2	110
129	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
130	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
131	Germinal center hypoxia in tumor-draining lymph nodes negatively regulates tumor-induced humoral immune responses in mouse models of breast cancer. <i>Oncolmmunology</i> , 2021, 10, 1959978.	2.1	4
132	Recent advances in the understanding and management of liposarcoma. <i>Faculty Reviews</i> , 2021, 10, 1.	1.7	24
133	B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma. , 2021, 7, .		10
134	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 674-679.	0.7	4
135	Lipid Metabolism in Tumor-Associated B Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1316, 133-147.	0.8	3
136	Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role. <i>Journal of Immunology</i> , 2021, 206, 273-281.	0.4	72
137	Epigenetic modulation of immunotherapy and implications in head and neck cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 141-152.	2.7	21
138	Characterization of Urine Stem Cell-Derived Extracellular Vesicles Reveals B Cell Stimulating Cargo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 459.	1.8	14
140	Immune-related prognostic genes signatures in the tumor microenvironment of sarcoma. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 2243-2257.	1.0	6
141	Relationship between Tertiary Lymphoid Structure and the Prognosis and Clinicopathologic Characteristics in Solid Tumors. <i>International Journal of Medical Sciences</i> , 2021, 18, 2327-2338.	1.1	13
142	Physics approaches to the spatial distribution of immune cells in tumors. <i>Reports on Progress in Physics</i> , 2021, 84, 022601.	8.1	10
143	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8 ⁺ T-Cell Exhaustion. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1036-1043.	3.0	50
144	Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2179-2195.	2.0	22
145	Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2021, 2265, 573-587.	0.4	7
146	Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 590-606.	1.3	25

#	ARTICLE	IF	CITATIONS
147	Multi-Dimensional Biomarkers for the Personalized Treatment of Melanoma. , 2021, , 361-364.		1
148	Low KRT15 expression is associated with poor prognosis in patients with breast invasive carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 305.	0.8	18
149	The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. <i>Theranostics</i> , 2021, 11, 3565-3579.	4.6	20
151	Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models. <i>Scientific Reports</i> , 2021, 11, 1098.	1.6	10
152	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1377-1385.	1.2	15
153	Next-Generation Immunotherapies to Improve Anticancer Immunity. <i>Frontiers in Pharmacology</i> , 2020, 11, 566401.	1.6	8
154	T resident helper cells promote humoral responses in the lung. <i>Science Immunology</i> , 2021, 6, .	5.6	85
155	Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. <i>Oncolmmunology</i> , 2021, 10, 1900635.	2.1	73
156	CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. , 2021, 9, e001136.		85
157	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). <i>Cancers</i> , 2021, 13, 231.	1.7	42
158	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1860586.	2.1	40
159	Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma. <i>BMC Cancer</i> , 2021, 21, 144.	1.1	9
160	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. <i>Cancer</i> , 2021, 127, 1553-1567.	2.0	33
161	Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 687-697.	1.1	21
162	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patientsâ€™A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	1.7	17
163	CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 596.	1.7	24
164	Immunotherapy for sarcomas. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 523-537.	0.6	21
165	Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen. <i>Journal of Controlled Release</i> , 2021, 330, 753-764.	4.8	42

#	ARTICLE	IF	CITATIONS
166	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , 2021, 12, 935.	5.8	56
167	IgA transcytosis and antigen recognition govern ovarian cancer immunity. <i>Nature</i> , 2021, 591, 464-470.	13.7	99
168	NF- κ B in Cancer Immunity: Friend or Foe?. <i>Cells</i> , 2021, 10, 355.	1.8	38
171	Inflammatory Undifferentiated Pleomorphic Sarcoma Mimicking Bacteremia in an Elderly Patient: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 175.	0.8	3
172	Prognostic Gene Expression, Stemness and Immune Microenvironment in Pediatric Tumors. <i>Cancers</i> , 2021, 13, 854.	1.7	10
174	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 74.	3.5	19
176	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. <i>Nature Cancer</i> , 2021, 2, 218-232.	5.7	34
177	Modulation of the Vascular-Immune Environment in Metastatic Cancer. <i>Cancers</i> , 2021, 13, 810.	1.7	12
178	External cues to drive B cell function towards immunotherapy. <i>Acta Biomaterialia</i> , 2021, 133, 222-230.	4.1	13
179	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2617-2624.	2.0	45
180	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review. <i>Frontiers in Oncology</i> , 2020, 10, 585311.	1.3	69
181	Immunotherapy for sarcomas: new frontiers and unveiled opportunities. , 2021, 9, e001580.		48
182	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
183	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
184	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
185	Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. <i>Frontiers in Immunology</i> , 2021, 12, 629519.	2.2	10
186	B Cell Response to Vaccination. <i>Immunological Investigations</i> , 2021, 50, 780-801.	1.0	29
187	Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. <i>Nature Communications</i> , 2021, 12, 1613.	5.8	114

#	ARTICLE	IF	CITATIONS
188	PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. <i>BMC Cancer</i> , 2021, 21, 336.	1.1	4
190	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , 2021, 11, 2014-2031.	7.7	79
192	Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice. <i>Diagnostics</i> , 2021, 11, 512.	1.3	3
194	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 1680-1689.	2.9	37
195	Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2881-2892.	2.0	14
196	Gastrointestinal stromal tumours. <i>Nature Reviews Disease Primers</i> , 2021, 7, 22.	18.1	169
198	Research and application of hydrostatic high pressure in tumor vaccines (Review). <i>Oncology Reports</i> , 2021, 45, .	1.2	4
199	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3079-3093.	3.2	8
200	Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 115.	7.1	12
201	Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression. <i>Case Reports in Oncology</i> , 2021, 14, 459-465.	0.3	9
202	CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 1175.	1.7	2
203	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 626776.	2.2	39
204	Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. <i>Nature Communications</i> , 2021, 12, 1540.	5.8	88
205	NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 1561.	1.7	20
206	Highly multiplexed tissue imaging using repeated oligonucleotide exchange reaction. <i>European Journal of Immunology</i> , 2021, 51, 1262-1277.	1.6	53
207	Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. , 2021, 9, e001813.		57
208	Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1895-1909.	1.0	5
209	Anti-CD19 CAR T cells potently redirected to kill solid tumor cells. <i>PLoS ONE</i> , 2021, 16, e0247701.	1.1	14

#	ARTICLE	IF	CITATIONS
210	Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2669.	1.8	22
211	Vascular reconstitution in the tumor for more effective tumor immunotherapy. <i>Cancer Science</i> , 2021, 112, 1348-1356.	1.7	8
212	Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. <i>PLoS ONE</i> , 2021, 16, e0248903.	1.1	6
213	Vaincre les résistances aux antagonistes de checkpoint en augmentant l'immuno-génotoxicité de la tumeur. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2021, 205, 340-349.	0.0	0
214	Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 154, 221-223.	0.9	4
215	Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?. <i>Cancers</i> , 2021, 13, 1850.	1.7	38
216	A 4-gene-based hypoxia signature is associated with tumor immune microenvironment and predicts the prognosis of pancreatic cancer patients. <i>World Journal of Surgical Oncology</i> , 2021, 19, 123.	0.8	20
217	Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 668992.	1.3	3
218	Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the Immune Microenvironment of Chordoma Tissues. <i>Cancers</i> , 2021, 13, 2169.	1.7	10
219	Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. <i>Cancer Immunology Research</i> , 2021, 9, 365-370.	1.6	28
221	Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. <i>Cell Reports</i> , 2021, 35, 108948.	2.9	20
222	Application of Immune Infiltration Signature and Machine Learning Model in the Differential Diagnosis and Prognosis of Bone-Related Malignancies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 630355.	1.8	10
223	Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3031-3040.	2.0	9
224	Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. <i>Nature Communications</i> , 2021, 12, 2186.	5.8	86
225	Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2209-2222.	1.2	15
226	Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 142.	3.5	20
227	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
228	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	3.7	24

#	ARTICLE	IF	CITATIONS
229	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
230	Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1639.	1.7	13
231	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. <i>Scientific Reports</i> , 2021, 11, 9362.	1.6	14
232	Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3489-3499.	2.0	5
233	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	1.8	1
234	Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 147, 164-169.	1.3	13
235	Tumor-Associated Neutrophils Drive B-cell Recruitment and Their Differentiation to Plasma Cells. <i>Cancer Immunology Research</i> , 2021, 9, 811-824.	1.6	17
236	Integrated Analysis of Nine Prognostic RNA-Binding Proteins in Soft Tissue Sarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 633024.	1.3	6
238	Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 674558.	1.6	10
239	Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. <i>Journal of Translational Medicine</i> , 2021, 19, 204.	1.8	5
240	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021, 27, 820-832.	15.2	330
241	Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 673051.	1.6	10
242	Beneficial autoimmunity improves cancer prognosis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 591-602.	12.5	63
243	Stromal cells in tertiary lymphoid structures: Architects of autoimmunity. <i>Immunological Reviews</i> , 2021, 302, 184-195.	2.8	12
244	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021, 13, 2359.	1.7	6
245	Multiomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment. <i>Npj Genomic Medicine</i> , 2021, 6, 37.	1.7	7
246	Next-generation sequencing for the management of sarcomas with no known driver mutations. <i>Current Opinion in Oncology</i> , 2021, 33, 315-322.	1.1	13
248	Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 677944.	1.8	3

#	ARTICLE	IF	CITATIONS
249	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 148, 181-189.	1.3	70
250	High endothelial venules (HEVs) in immunity, inflammation and cancer. <i>Angiogenesis</i> , 2021, 24, 719-753.	3.7	64
251	Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling. <i>Frontiers in Immunology</i> , 2021, 12, 674375.	2.2	23
252	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4109-4125.	3.2	65
253	Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 674565.	2.2	28
254	Identification of CXCL13/CXCR5 axis's crucial and complex effect in human lung adenocarcinoma. <i>International Immunopharmacology</i> , 2021, 94, 107416.	1.7	7
255	IgA transcytosis: A new weapon in the immune response to cancer?. <i>Cancer Cell</i> , 2021, 39, 607-609.	7.7	2
256	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 558-576.	12.5	202
257	Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. , 2021, 9, e001772.		42
258	Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients. <i>Aging</i> , 2021, 13, 12896-12918.	1.4	18
259	The Immunology of Hormone Receptor Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 674192.	2.2	68
260	Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 2771.	1.7	5
261	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
262	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6741.	1.8	28
263	B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 678127.	1.8	63
264	B cells and their role in shaping the immune response in squamous cell carcinoma of the head and neck. <i>Immunotherapy</i> , 2021, 13, 723-726.	1.0	2
265	Checkpoint blockade accelerates a novel switch from an NKT-driven TNF± response toward a T cell driven IFN-β response within the tumor microenvironment. , 2021, 9, e002269.		2
266	The prospects of nanotherapeutic approaches for targeting tumor-associated macrophages in oral cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 34, 102371.	1.7	6

#	ARTICLE	IF	CITATIONS
267	The neglected brothers come of age: B cells and cancer. <i>Seminars in Immunology</i> , 2021, 52, 101479.	2.7	28
269	CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1098-1108.	1.6	38
270	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. <i>Nature Immunology</i> , 2021, 22, 1052-1063.	7.0	61
271	Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells. <i>Cancers</i> , 2021, 13, 3298.	1.7	5
273	Talimogene laherparepvec (TVEC) pseudolymphomatous reaction mimicking metastatic melanoma. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1423-1426.	0.7	3
274	Turning “Cold” tumors “Hot”: immunotherapies in sarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1039-1039.	0.7	21
275	Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. <i>Cancers</i> , 2021, 13, 3044.	1.7	20
276	A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression-and Tumor Site-Associated Changes With Germinal Center Alteration. <i>Frontiers in Immunology</i> , 2021, 12, 675146.	2.2	31
277	Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. <i>Frontiers in Immunology</i> , 2021, 12, 698604.	2.2	35
278	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19
279	Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. <i>Journal of Hematology and Oncology</i> , 2021, 14, 98.	6.9	173
280	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. <i>Cancer Cell</i> , 2021, 39, 845-865.e7.	7.7	503
281	The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. <i>Frontiers in Immunology</i> , 2021, 12, 694079.	2.2	10
282	B cells in lung cancer “not just a bystander cell: a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2830-2841.	1.3	20
283	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. <i>Clinical Cancer Research</i> , 2021, 27, 4500-4510.	3.2	8
284	Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 698465.	1.3	7
285	Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 589022.	1.3	20
286	Prognostic value of tertiary lymphoid structures in early clinical stage oral tongue squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 776-784.	1.4	6

#	ARTICLE	IF	CITATIONS
287	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 3349.	5.8	142
288	Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e422.	1.7	47
289	Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2021, 21, 310.	1.8	21
290	B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. <i>Oncogene</i> , 2021, 40, 4737-4745.	2.6	16
291	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. <i>Clinical Cancer Research</i> , 2021, 27, 4781-4793.	3.2	14
292	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters. <i>Frontiers in Immunology</i> , 2021, 12, 690112.	2.2	42
293	TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. <i>Cancers</i> , 2021, 13, 3362.	1.7	6
294	CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer. <i>European Journal of Cancer</i> , 2021, 151, 245-248.	1.3	14
295	Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells. <i>Cancer Research</i> , 2021, 81, 5047-5059.	0.4	28
296	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
298	Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. <i>Diagnostics</i> , 2021, 11, 1238.	1.3	6
299	Role of reactive oxygen species in tumors based on the “seed and soil” theory: A complex interaction (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	15
300	Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. <i>Clinical Cancer Research</i> , 2021, 27, 6075-6082.	3.2	40
301	Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. <i>Cancers</i> , 2021, 13, 3678.	1.7	37
302	Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7518.	1.8	17
303	Clinical and immunological characteristics of sarcomas patients with clonogenic tumors. <i>Immunobiology</i> , 2021, 226, 152094.	0.8	0
304	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
305	Tertiary lymphoid structures correlate with better prognosis in cutaneous angiosarcoma. <i>Journal of Dermatological Science</i> , 2021, 103, 57-59.	1.0	6

#	ARTICLE	IF	CITATIONS
307	Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 152, 165-182.	1.3	60
308	Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. <i>BMC Cancer</i> , 2021, 21, 862.	1.1	6
309	Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. <i>Npj Breast Cancer</i> , 2021, 7, 84.	2.3	16
310	SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1508-1520.	1.9	8
311	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021, 152, 155-164.	1.3	21
312	Breast cancer resistance mechanisms: challenges to immunotherapy. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 5-17.	1.1	16
313	Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 689270.	2.2	40
314	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 891-903.	5.7	147
315	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. <i>Nature Medicine</i> , 2021, 27, 1250-1261.	15.2	159
316	PD-1 ^{hi} CXCR5 ^{hi} CD4 ^{hi} Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. , 2021, 9, e002101.		30
317	Targeting Neopeptides to Treat Solid Malignancies: Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 592031.	2.2	6
318	The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade. <i>PLoS ONE</i> , 2021, 16, e0253864.	1.1	3
319	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. <i>Cell Reports</i> , 2021, 36, 109422.	2.9	89
320	Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. <i>Communications Biology</i> , 2021, 4, 859.	2.0	13
321	Lineage Reprogramming of Effector Regulatory T Cells in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 717421.	2.2	12
322	Tertiary lymphoid tissues: a regional hub for kidney inflammation. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 26-33.	0.4	11
323	Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma. <i>EBioMedicine</i> , 2021, 69, 103459.	2.7	62
324	The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis. <i>Cancers</i> , 2021, 13, 3335.	1.7	14

#	ARTICLE	IF	CITATIONS
325	CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. , 2021, 9, e002812.		21
326	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nature Communications, 2021, 12, 5137.	5.8	63
327	Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 514-528.	0.4	11
328	Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy. Cancers, 2021, 13, 3885.	1.7	12
329	Advances in technology and applications of nanoimmunotherapy for cancer. Biomarker Research, 2021, 9, 63.	2.8	7
330	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2021, 2, 794-802.	5.7	173
331	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Cancer Discovery, 2022, 12, 47-61.	7.7	58
332	Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Frontiers in Immunology, 2021, 12, 715727.	2.2	18
333	Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers, 2021, 13, 4280.	1.7	16
334	High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer. Frontiers in Immunology, 2021, 12, 736670.	2.2	26
335	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. Biomedicines, 2021, 9, 1048.	1.4	6
336	Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nature Communications, 2021, 12, 5291.	5.8	98
337	Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. Frontiers in Molecular Biosciences, 2021, 8, 673042.	1.6	19
338	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 744889.	1.3	19
339	Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients. Translational Lung Cancer Research, 2021, 10, 3807-3822.	1.3	11
340	Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma. Scientific Reports, 2021, 11, 18875.	1.6	13
341	The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , .		0
342	A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 706915.	1.3	8

#	ARTICLE	IF	CITATIONS
343	Spatially organized multicellular immune hubs in human colorectal cancer. <i>Cell</i> , 2021, 184, 4734-4752.e20.	13.5	256
344	A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy. <i>Cell Discovery</i> , 2021, 7, 80.	3.1	55
345	Genome edited B cells: a new frontier in immune cell therapies. <i>Molecular Therapy</i> , 2021, 29, 3192-3204.	3.7	9
346	Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. <i>Cancers</i> , 2021, 13, 4816.	1.7	25
347	Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells. <i>Advanced Materials</i> , 2021, 33, e2104849.	11.1	52
348	Refining patient selection for breast cancer immunotherapy: beyond PD-L1. <i>ESMO Open</i> , 2021, 6, 100257.	2.0	13
349	Emerging roles for IL-6 family cytokines as positive and negative regulators of ectopic lymphoid structures. <i>Cytokine</i> , 2021, 146, 155650.	1.4	5
350	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	70
351	PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity. <i>Journal of Controlled Release</i> , 2021, 339, 156-163.	4.8	12
352	Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188606.	3.3	18
353	Comparison of therapeutic strategies for immuno-oncology. , 2022, , 439-461.		0
354	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
355	New therapeutic advances of bone sarcomas. , 2022, , 755-766.		0
356	Innate and adaptive immunity in cancer. , 2022, , 19-61.		0
357	Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy. <i>Cancers</i> , 2021, 13, 498.	1.7	25
358	B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1882743.	2.1	11
359	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 622442.	2.2	39
360	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2021, 10, 1929724.	2.1	22

#	ARTICLE	IF	CITATIONS
361	Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. <i>Oncolmmunology</i> , 2021, 10, 1900508.	2.1	57
362	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , 2021, 27, 141-151.	15.2	134
363	Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 490.	1.0	12
364	Jia You (2021). <i>Journal of Cancer Research and Practice</i> , 2021, 8, 39.	0.2	0
365	A novel cancer immunotherapy using tumor-infiltrating B cells in the APCmin/+ mouse model. <i>PLoS ONE</i> , 2021, 16, e0245608.	1.1	6
366	Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2021, 10, 1915574.	2.1	21
367	The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches. <i>Cancers</i> , 2021, 13, 363.	1.7	11
368	T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN- γ , TNF- α or IL-2 production. <i>Oncolmmunology</i> , 2021, 10, 1860482.	2.1	16
369	B Cells in the Gastrointestinal Tumor Microenvironment with a Focus on Pancreatic Cancer: Opportunities for Precision Medicine?. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 175-195.	0.8	2
370	Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". <i>British Journal of Cancer</i> , 2021, 124, 1179-1180.	2.9	3
371	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	91
379	Regulatory B cells in cancer. <i>Immunological Reviews</i> , 2021, 299, 74-92.	2.8	75
380	Effects of B cell-activating factor on tumor immunity. <i>JCI Insight</i> , 2020, 5, .	2.3	27
381	Comprehensive analysis of immune infiltration and gene expression for predicting survival in patients with sarcomas. <i>Aging</i> , 2021, 13, 2168-2183.	1.4	9
382	https://cdrjournal.com/article/view/3531 . , 2020, 3, 454-471.		4
383	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
384	T _{FR} Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
385	B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia. <i>Clinical Hematology International</i> , 2020, 2, 125.	0.7	3

#	ARTICLE	IF	CITATIONS
386	When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 69-82.	0.6	2
388	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
389	The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma. <i>PeerJ</i> , 2020, 8, e9736.	0.9	9
390	Tumor-Associated Tertiary Lymphoid Structures: A Cancer Biomarker and a Target for Next-generation Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 51-68.	0.8	7
391	Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer. <i>Oncolmmunology</i> , 2021, 10, 1987636.	2.1	81
392	Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab. <i>Frontiers in Oncology</i> , 2021, 11, 728437.	1.3	2
393	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. <i>Cancer Cell</i> , 2021, 39, 1578-1593.e8.	7.7	275
394	Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 42-56.	0.6	56
395	Targeted Anti-tumor Immunotherapy Using Tumor Infiltrating Cells. <i>Advanced Science</i> , 2021, 8, e2101672.	5.6	36
396	Impact of the ileal microbiota on colon cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 955-966.	4.3	11
397	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
398	Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer. <i>Nature Communications</i> , 2021, 12, 6068.	5.8	31
399	Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1431-1442.	2.0	15
400	Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy (Review). <i>Oncology Letters</i> , 2021, 22, 836.	0.8	16
401	Knockdown of DIAPH3 Inhibits the Proliferation of Cervical Cancer Cells through Inactivating mTOR Signaling Pathway. <i>Journal of Oncology</i> , 2021, 2021, 1-16.	0.6	8
402	Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. <i>Clinical Cancer Research</i> , 2022, 28, 215-226.	3.2	5
403	The tumor immune microenvironments of HPV ⁺ and HPV ⁻ head and neck cancers. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1539.	1.5	13
404	The perplexing role of immuno-oncology drugs in osteosarcoma. <i>Journal of Bone Oncology</i> , 2021, 31, 100400.	1.0	4

#	ARTICLE	IF	CITATIONS
405	Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. <i>Oncogenesis</i> , 2021, 10, 71.	2.1	24
406	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 158, 123-132.	1.3	11
407	Significance of intratumoral infiltration of B cells in cancer immunotherapy: From a single cell perspective. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188632.	3.3	7
409	Prognostic and predictive role of the tumor immune landscape. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 143-151.	0.4	3
410	Local cellular cues that influence the immunology of colorectal cancer treatment. <i>Nature Medicine</i> , 2020, 26, 824-826.	15.2	2
413	The complexity of immune cell landscape in hepatocellular carcinomas with different risksâ€”reply letter. <i>Annals of Translational Medicine</i> , 2020, 8, 729-729.	0.7	0
417	Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis. <i>Medicine (United States)</i> , 2021, 100, e27650.	0.4	5
418	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
419	The Role of B Cells in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5383.	1.7	10
420	Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1479-1495.	2.0	4
421	Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer. <i>Annals of Oncology</i> , 2021, , .	0.6	0
428	A prognostic fibroblast-related risk signature in colorectal cancer. <i>Aging</i> , 2021, 13, 24251-24270.	1.4	1
429	WNT/ β -Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?. <i>Cancers</i> , 2021, 13, 5521.	1.7	7
430	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	5.8	22
431	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021, 21, 1180.	1.1	9
433	Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study. <i>PeerJ</i> , 2020, 8, e9779.	0.9	2
435	Interactions between tumor mutation burden and immune infiltration in ovarian cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2513-2523.	0.5	2
436	Bone invasion in soft tissue sarcomas of the extremities: An underappreciated prognostic factor. <i>Bone invasion in soft tissue sarcomas. Surgical Oncology</i> , 2022, 40, 101692.	0.8	1

#	ARTICLE	IF	CITATIONS
437	Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade. <i>Molecular Cancer</i> , 2021, 20, 150.	7.9	31
438	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675.		24
439	Integrated analysis of immune infiltration in esophageal carcinoma as prognostic biomarkers. <i>Annals of Translational Medicine</i> , 2021, 9, 1697-1697.	0.7	4
440	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 710943.	1.6	6
441	Sequential modulation of the Wnt/ β -catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance. <i>Gynecologic Oncology</i> , 2022, 164, 170-180.	0.6	10
442	Neoantigen-driven B cell and CD4 ⁺ follicular helper cell collaboration promotes anti-tumor CD8 T _H cell responses. <i>Cell</i> , 2021, 184, 6101-6118.e13.	13.5	192
443	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 759217.	2.2	18
444	Immune activity in Merkel cell carcinoma. <i>Journal of Dermatology</i> , 2021, 49, 68.	0.6	2
445	TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma. <i>Molecules and Cells</i> , 2021, 44, 784-794.	1.0	4
446	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9031-9049.	0.8	0
447	Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 761798.	2.2	2
448	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	0
449	Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 747650.	1.6	15
450	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2022, 76, 608-618.	1.8	62
451	Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells. <i>Frontiers in Immunology</i> , 2021, 12, 783370.	2.2	5
452	CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. <i>Life</i> , 2021, 11, 1282.	1.1	18
453	Adult Soft-Tissue Sarcomas of the Extremities. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 379-389.	1.4	8
454	Comprehensive gene cluster analysis of head and neck squamous cell carcinoma TCGA RNA-seq data defines B cell immunity-related genes as a robust survival predictor. <i>Head and Neck</i> , 2021, , .	0.9	5

#	ARTICLE	IF	CITATIONS
455	Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. PLoS ONE, 2021, 16, e0260500.	1.1	2
456	Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors. Biomedicines, 2021, 9, 1798.	1.4	6
457	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 5981.	1.7	31
458	Prognostic value of immune-related genes and comparative analysis of immune cell infiltration in lung adenocarcinoma: sex differences. Biology of Sex Differences, 2021, 12, 64.	1.8	8
459	Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity, 2021, 54, 2812-2824.e4.	6.6	99
460	Pyroptosis-Related Gene Signature Is a Novel Prognostic Biomarker for Sarcoma Patients. Disease Markers, 2021, 2021, 1-13.	0.6	4
462	Single-Cell Atlas of Infiltrating B Cells and Their Clinical Outcomes in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
463	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. Frontiers in Immunology, 2021, 12, 790119.	2.2	7
464	Tertiary lymphoid structures in cancer. Science, 2022, 375, eabf9419.	6.0	303
465	Accounting for B-cell Behavior and Sampling Bias Predicts Anti-PD-L1 Response in Bladder Cancer. Cancer Immunology Research, 2022, 10, 343-353.	1.6	9
466	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell, 2022, 40, 70-87.e15.	7.7	120
467	A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Medicine, 2022, 14, 5.	3.6	25
468	B cells imprint adoptively transferred CD8 ⁺ T cells with enhanced tumor immunity. , 2022, 10, e003078.		7
469	Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals. European Journal of Cancer, 2022, 162, 130-132.	1.3	0
470	A novel immune-related gene signature predicting survival in sarcoma patients. Molecular Therapy - Oncolytics, 2022, 24, 114-126.	2.0	8
471	Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. Immunologic Research, 2022, 70, 256-268.	1.3	4
472	A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer. Thoracic Cancer, 2022, , .	0.8	4
473	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Frontiers in Immunology, 2021, 12, 808964.	2.2	53

#	ARTICLE	IF	CITATIONS
474	Role of adjuvant chemotherapy in patients with localized, undifferentiated pleomorphic sarcoma of soft tissue: a population-based cohort study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 802-810.	1.0	4
475	Engineering interferons and interleukins for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114112.	6.6	54
476	CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 770811.	1.8	4
477	Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor- $\hat{\pm}$ in B cell responses. <i>Oncogene</i> , 2022, 41, 1434-1444.	2.6	1
478	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. <i>Medicinal Research Reviews</i> , 2022, 42, 1246-1279.	5.0	38
479	Prevalence and Spectrum of Predisposition Genes With Germline Mutations Among Chinese Patients With Bowel Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 755629.	1.1	1
480	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793992.	2.2	14
481	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1923-1935.	2.0	19
482	Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. <i>OncImmunity</i> , 2022, 11, 2027148.	2.1	11
483	Soft Tissue Tumors. <i>Radiologic Clinics of North America</i> , 2022, 60, 283-299.	0.9	2
484	Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	71
485	Immunological and prognostic significance of novel ferroptosis-related genes in soft tissue sarcoma. <i>PLoS ONE</i> , 2022, 17, e0262234.	1.1	2
486	Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling. , 2022, 10, e003325.		7
487	B cell-derived IL-27 promotes control of persistent LCMV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
488	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
490	Development and Validation of a Pyroptosis-Related Signature for Predicting Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 801419.	1.1	7
491	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1310-1317.	2.9	7
492	Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 794217.	2.2	4

#	ARTICLE	IF	CITATIONS
493	Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles. <i>Science Immunology</i> , 2022, 7, eabf5314.	5.6	38
494	Discovering dominant tumor immune archetypes in a pan-cancer census. <i>Cell</i> , 2022, 185, 184-203.e19.	13.5	70
495	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	2.0	0
496	WT1 epitope-specific IgG and IgM antibodies for immune monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine. <i>Oncology Letters</i> , 2022, 23, 65.	0.8	3
497	B Cell Function in the Tumor Microenvironment. <i>Annual Review of Immunology</i> , 2022, 40, 169-193.	9.5	84
498	Clinical characteristics of undifferentiated pleomorphic sarcoma of bone and the impact of adjuvant chemotherapy on the affected patients: a population-based cohort study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 589-598.	0.6	2
499	Impact of tissue-agnostic approvals for patients with sarcoma. <i>Trends in Cancer</i> , 2022, 8, 135-144.	3.8	11
500	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	2.9	45
501	Immunotherapy resistance of lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 114-128.	0.9	0
502	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, 501-511.	1.9	14
503	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2022, 40, 318-334.e9.	7.7	97
504	New developments in the pathology and molecular biology of retroperitoneal sarcomas. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1053-1060.	0.5	6
505	Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. <i>Clinical Cancer Research</i> , 2022, 28, 1701-1711.	3.2	17
506	Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance. <i>Clinical Cancer Research</i> , 2022, 28, 1712-1723.	3.2	3
507	Tertiary lymphoid structure and decreased CD8+ T cell infiltration in minimally invasive adenocarcinoma. <i>IScience</i> , 2022, 25, 103883.	1.9	3
508	LLT1-CD161 Interaction in Cancer: Promises and Challenges. <i>Frontiers in Immunology</i> , 2022, 13, 847576.	2.2	15
509	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
510	B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?. <i>Clinical Cancer Research</i> , 2022, 28, 1751-1758.	3.2	39

#	ARTICLE	IF	CITATIONS
511	Emerging mechanisms of immunotherapy resistance in sarcomas. <i>Cancer Drug Resistance (Alhambra)</i> , 2022, 10, 107-114.	0.9	1
512	Immune checkpoint inhibitor resistance in soft tissue sarcoma. <i>Cancer Drug Resistance (Alhambra)</i> , 2022, 10, 115-122.	0.9	4
513	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. <i>Biomedicines</i> , 2022, 10, 573.	1.4	8
514	Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2022, 6, 10.	2.3	23
515	Building the Canadian Bladder Cancer Research Network (CBCRN): Progress During a Pandemic. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	0
516	Biomarkers of response to PD-1 pathway blockade. <i>British Journal of Cancer</i> , 2022, 126, 1663-1675.	2.9	52
517	Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial. <i>BMC Cancer</i> , 2022, 22, 169.	1.1	4
519	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	3.3	13
520	Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). <i>Nature Communications</i> , 2022, 13, 857.	5.8	50
521	Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival. <i>Cancer Immunology Research</i> , 2022, 10, 468-481.	1.6	14
522	Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment. <i>Scientific Reports</i> , 2022, 12, 3278.	1.6	25
523	Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. <i>Cell Research</i> , 2022, 32, 530-542.	5.7	54
524	A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 730132.	1.8	7
525	Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 3079.	1.6	6
526	IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 857289.	1.6	10
527	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. <i>Nature Communications</i> , 2022, 13, 1373.	5.8	47
528	B cells in pancreatic cancer stroma. <i>World Journal of Gastroenterology</i> , 2022, 28, 1088-1101.	1.4	17
529	A high-resolution view of intra-tumoral B cell immunity. <i>Immunity</i> , 2022, 55, 387-389.	6.6	4

#	ARTICLE	IF	CITATIONS
530	Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. , 2022, 10, e003883.		13
531	A Bâ€cell or a key player? The different roles of Bâ€cells and antibodies in melanoma. Pigment Cell and Melanoma Research, 2022, 35, 303-319.	1.5	5
532	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nature Immunology, 2022, 23, 660-670.	7.0	191
533	What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. Current Treatment Options in Oncology, 2022, 23, 439-449.	1.3	5
534	The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. Biomarker Research, 2022, 10, 9.	2.8	28
535	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell, 2022, 40, 289-300.e4.	7.7	148
536	Tumor-Draining Lymph Node Reconstruction Promotes B Cell Activation During E0771 Mouse Breast Cancer Growth. Frontiers in Pharmacology, 2022, 13, 825287.	1.6	3
537	Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?. Cancer Cell, 2022, 40, 240-243.	7.7	4
538	Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. Biomedicines, 2022, 10, 650.	1.4	24
539	Editorial: Tertiary Lymphoid Structures: From Basic Biology to Translational Impact in Cancer. Frontiers in Immunology, 2022, 13, 870862.	2.2	2
540	A Multidisciplinary Approach to Complex Dermal Sarcomas Ensures an Optimal Clinical Outcome. Cancers, 2022, 14, 1693.	1.7	3
541	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 2022, 55, 527-541.e5.	6.6	215
542	Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell, 2022, 185, 1208-1222.e21.	13.5	59
543	Immunotherapy and Biomarkers in Sarcoma. Current Treatment Options in Oncology, 2022, 23, 415-438.	1.3	12
544	Locally produced autoantibodies in cancer. Cell, 2022, 185, 1110-1111.	13.5	0
545	Immunotherapy for Sarcoma: A Work in Progress. Journal of Clinical Oncology, 2022, 40, 1267-1270.	0.8	6
546	Exploration of Reduced Mitochondrial Contentâ€Associated Gene Signature and Immunocyte Infiltration in Colon Adenocarcinoma by an Integrated Bioinformatic Analysis. Frontiers in Genetics, 2022, 13, 832331.	1.1	1
547	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176

#	ARTICLE	IF	CITATIONS
548	Two sides of the same coin: Protective versus pathogenic CD4 ⁺ resident memory T cells. <i>Science Immunology</i> , 2022, 7, eabf9393.	5.6	11
549	PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2061396.	2.1	20
550	Stemness Subtypes and Scoring System Predict Prognosis and Efficacy of Immunotherapy in Soft Tissue Sarcoma. <i>Frontiers in Immunology</i> , 2022, 13, 796606.	2.2	3
551	Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. <i>Nature Reviews Cancer</i> , 2022, 22, 414-430.	12.8	109
552	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
553	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. <i>EBioMedicine</i> , 2022, 78, 103958.	2.7	15
554	Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer. <i>International Immunopharmacology</i> , 2022, 106, 108630.	1.7	7
555	Multimodal predictors for precision immunotherapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100071.	0.2	4
556	Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. <i>Cancer Letters</i> , 2022, 535, 215661.	3.2	12
557	Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies. <i>Cancer Biology and Medicine</i> , 2021, 18, 981-991.	1.4	14
558	Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 1765-1772.	3.2	17
559	Tfh cells set the stage for tumor control. <i>Immunity</i> , 2021, 54, 2690-2692.	6.6	4
560	m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma. <i>Frontiers in Immunology</i> , 2021, 12, 765723.	2.2	8
561	Cancer-immunotherapy biomarkers in the tumor microenvironment. <i>Okayama Igakkai Zasshi</i> , 2021, 133, 151-157.	0.0	0
562	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	3.2	10
563	An AutoEncoder-Based Matrix Factorization Approach to Estimating Cell Proportion from Bulk Tumor RNA-seq Data. , 2021, , .		0
564	Unravelling undifferentiated soft tissue sarcomas: insights from genomics. <i>Histopathology</i> , 2022, 80, 109-121.	1.6	3
565	Focus on organoids: cooperation and interconnection with extracellular vesicles – Is this the future of in vitro modeling?. <i>Seminars in Cancer Biology</i> , 2022, 86, 367-381.	4.3	5

#	ARTICLE	IF	CITATIONS
566	Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target. <i>Oncology Reports</i> , 2021, 47, .	1.2	8
567	EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	3
568	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. <i>Frontiers in Immunology</i> , 2021, 12, 775761.	2.2	45
569	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. <i>Cancer Research</i> , 2022, 82, 859-871.	0.4	21
570	Tertiary lymphoid structure stratifies glioma into three distinct tumor subtypes. <i>Aging</i> , 2021, 13, 26063-26094.	1.4	5
571	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	1.7	0
572	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 405.	1.8	11
574	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
575	Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 491-503.	1.1	8
576	Targeting the gut and tumor microbiota in cancer. <i>Nature Medicine</i> , 2022, 28, 690-703.	15.2	159
577	Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. <i>Cancers</i> , 2022, 14, 1999.	1.7	5
578	Mapping Breast Cancer Microenvironment Through Single-Cell Omics. <i>Frontiers in Immunology</i> , 2022, 13, 868813.	2.2	18
579	Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 865964.	2.2	9
580	Breast tumor microenvironment structures are associated with genomic features and clinical outcome. <i>Nature Genetics</i> , 2022, 54, 660-669.	9.4	88
595	Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. <i>European Journal of Histochemistry</i> , 2022, 66, .	0.6	3
596	T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. <i>Nature Communications</i> , 2022, 13, 2259.	5.8	32
597	Enrichment of Tumor-Infiltrating B Cells in Group 4 Medulloblastoma in Children. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5287.	1.8	4
598	CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
599	Identification of TRP-Related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	1
600	Spatial determinants of CD8+ T cell differentiation in cancer. <i>Trends in Cancer</i> , 2022, 8, 642-654.	3.8	8
601	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	3.2	26
602	OX40 and 4-1BB delineate distinct immune profiles in sarcoma. <i>OncoImmunology</i> , 2022, 11, 2066050.	2.1	6
603	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	48
604	Immunofibroblasts regulate LT α 3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. <i>Communications Biology</i> , 2022, 5, 413.	2.0	8
605	Tumour immunotherapy: lessons from predatorâ€“prey theory. <i>Nature Reviews Immunology</i> , 2022, 22, 765-775.	10.6	41
606	A Multi-Omics Study on the Effect of Helicobacter Pylori-Related Genes in the Tumor Immunity on Stomach Adenocarcinoma. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	5
607	Cancerâ€“associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. <i>Journal of Pathology</i> , 2022, 257, 526-544.	2.1	27
608	High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 105-112.	2.0	2
609	Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
610	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.	5.1	49
611	Cancer evolution: special focus on the immune aspect of cancer. <i>Seminars in Cancer Biology</i> , 2022, , .	4.3	4
612	T cell help in the autoreactive germinal center. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13192.	1.3	4
613	Antibody repertoire sequencing analysis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	2
614	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
615	The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	21
617	Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
618	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
619	Intratumoral immunotherapy relies on B and T cell collaboration. <i>Science Immunology</i> , 2022, 7, .	5.6	17
620	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
621	Turning cold tumors hot: from molecular mechanisms to clinical applications. <i>Trends in Immunology</i> , 2022, 43, 523-545.	2.9	176
622	Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies. <i>Cancer Immunology Research</i> , 2022, 10, 788-799.	1.6	10
623	Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. <i>Genes</i> , 2022, 13, 951.	1.0	2
624	Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. <i>Seminars in Cancer Biology</i> , 2022, 84, 228-241.	4.3	7
625	Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	33
626	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5786.	1.8	9
627	Tumor-Resident T Cells, Associated With Tertiary Lymphoid Structure Maturity, Improve Survival in Patients With Stage III Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
628	The Molecular Biology of Soft Tissue Sarcomas: Current Knowledge and Future Perspectives. <i>Cancers</i> , 2022, 14, 2548.	1.7	6
629	Leucine-tRNA-synthetase-2-expressing B cells contribute to colorectal cancer immunoevasion. <i>Immunity</i> , 2022, 55, 1067-1081.e8.	6.6	21
630	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
631	Cluster of differentiation frequency on antigen presenting-cells: The next step to cervical cancer prognosis?. <i>International Immunopharmacology</i> , 2022, 108, 108896.	1.7	2
632	Tumor Immune Microenvironment of Soft Tissue Sarcoma. , 2022, , 639-647.		1
634	B-Cell-Based Immunotherapy: A Promising New Alternative. <i>Vaccines</i> , 2022, 10, 879.	2.1	10
635	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	28
636	The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma. <i>PeerJ</i> , 0, 10, e12588.	0.9	5

#	ARTICLE	IF	CITATIONS
637	Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. <i>Cancers</i> , 2022, 14, 3123.	1.7	5
638	Single-cell RNA-seq of a soft-tissue sarcoma model reveals the critical role of tumor-expressed MIF in shaping macrophage heterogeneity. <i>Cell Reports</i> , 2022, 39, 110977.	2.9	17
639	Emerging Biomaterials Imaging Antitumor Immune Response. <i>Advanced Materials</i> , 2022, 34, .	11.1	22
640	Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. <i>Pharmacological Reviews</i> , 2022, 74, 714-770.	7.1	95
641	Gastric cancer and genomics: review of literature. <i>Journal of Gastroenterology</i> , 2022, 57, 505-516.	2.3	19
642	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	21
643	The immune cell atlas of human neuroblastoma. <i>Cell Reports Medicine</i> , 2022, 3, 100657.	3.3	17
644	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
645	Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. <i>Nature Communications</i> , 2022, 13, .	5.8	17
646	Emergence of the CD226 Axis in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
647	Leiomyosarcoma. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 527-546.	0.6	9
648	The Cancer Genome Atlas. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 559-568.	0.6	4
649	Immunotherapy in Sarcoma. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 381-397.	0.6	9
650	Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. <i>European Journal of Cancer</i> , 2022, 172, 1-12.	1.3	7
651	Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 73.	0.1	0
652	The Impact of Tertiary Lymphoid Structures on Clinicopathological, Genetic and Gene Expression Characteristics in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
654	Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
655	Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. <i>Archives of Pharmacal Research</i> , 2022, 45, 401-416.	2.7	32

#	ARTICLE	IF	CITATIONS
656	Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
657	B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
658	Les structures lymphoÃdes tertiaires gÃnÃrent et propagent des plasmocytes produisant desÃanticorps antitumoraux dans le cancer du rein. <i>Medecine/Sciences</i> , 2022, 38, 536-538.	0.0	0
659	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
660	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. <i>Cancer</i> , 0, , .	2.0	0
661	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	5.8	9
662	Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2963-2974.	1.2	3
663	Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
664	Immunotherapy approaches for malignant pleural mesothelioma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 573-584.	12.5	21
665	Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation. <i>Oncolmmunology</i> , 2022, 11, .	2.1	14
667	Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
668	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 3383-3391.	2.0	9
669	Patient-Derived Sarcoma Organoids Offer a Novel Platform for Personalized Precision Medicine. <i>Annals of Surgical Oncology</i> , 2022, 29, 7239-7241.	0.7	3
670	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
671	Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
672	Peripheral Helper T Cell Responses in Human Diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
673	Interplay Between Immune and Cancer-Associated Fibroblasts: A Path to Target Metalloproteinases in Penile Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
674	First and further-line multidisciplinary treatment of retroperitoneal sarcomas. <i>Current Opinion in Oncology</i> , 2022, 34, 328-334.	1.1	2

#	ARTICLE	IF	CITATIONS
675	Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
676	Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
677	Editorial: precision medicine of sarcomas and aggressive connective tissue tumours: from one-size-fits-all to haute couture. <i>Current Opinion in Oncology</i> , 2022, 34, 320-321.	1.1	0
678	Immune-Cell-Derived Exosomes for Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2022, 19, 3042-3056.	2.3	15
679	Features and clinical significance of tertiary lymphoid structure in cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2043-2050.	1.3	6
680	Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
681	PD-1 TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4893-4906.	3.2	18
682	Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. , 2022, 10, e004892.		20
683	Across-Cancer Immune Responses Induced by Nanovaccines or Microvaccines to Prevent Different Cancers and Cancer Metastasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
684	Diversification and shared features of tumor-binding antibody repertoires in tumor, sentinel lymph node and blood of three patients with breast cancer. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	1
685	PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. <i>Nature Immunology</i> , 2022, 23, 1183-1192.	7.0	36
686	Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice. <i>Translational Cancer Research</i> , 2022, 11, 2388-2397.	0.4	1
687	Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. <i>Science Advances</i> , 2022, 8, .	4.7	10
688	Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
689	Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8489.	1.8	3
691	Stem-like T cells and niches: Implications in human health and disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
692	Neutrophils: Musketeers against immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
693	Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. <i>Immunology</i> , 2023, 168, 135-151.	2.0	25

#	ARTICLE	IF	CITATIONS
696	Tertiary Lymphoid Structures as Mediators of Immunotherapy Response. <i>Cancers</i> , 2022, 14, 3748.	1.7	14
697	<i>Escherichia coli</i> Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. <i>Cancer Discovery</i> , 2022, 12, 2280-2307.	7.7	23
698	A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-19.	0.7	4
699	Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 1010-1026.e11.	7.7	47
700	Evaluation of the Role of the Immune System Response After Minibeam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 426-439.	0.4	13
701	Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study. <i>Cancer Medicine</i> , 2023, 12, 3160-3166.	1.3	4
702	High endothelial venules as potential gateways for therapeutics. <i>Trends in Immunology</i> , 2022, 43, 728-740.	2.9	7
703	Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. , 2022, 10, e005328.		6
704	A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 5058-5065.	3.2	6
705	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
706	The role of B cells in the development, progression, and treatment of lymphomas and solid tumors. <i>Advances in Immunology</i> , 2022, , 71-117.	1.1	0
707	New opportunities for immunomodulation of the tumour microenvironment using chemical tools. <i>Chemical Society Reviews</i> , 2022, 51, 7944-7970.	18.7	15
708	TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, 21, 337-348.	3.0	17
709	Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
710	Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. <i>Clinical Cancer Research</i> , 2022, 28, 4968-4982.	3.2	16
711	Opsoclonus-Myoclonus syndrome associated with neuroblastoma: Insights into antitumor immunity. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	0.8	1
712	Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 7297-7311.	0.7	12
713	Biomarkers for immune checkpoint inhibitors in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 126-136.	1.2	3

#	ARTICLE	IF	CITATIONS
714	Identification of N6-methyladenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
715	Machine learning identifies exosome features related to hepatocellular carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
716	Role of B cells as antigen presenting cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	44
717	Nucleic acidâ€“triggered tumoral immunity propagates <sc>pH</sc>â€“selective therapeutic antibodies through tumorâ€“driven epitope spreading. <i>Cancer Science</i> , 2023, 114, 321-338.	1.7	2
718	Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. <i>Cell Reports Medicine</i> , 2022, 3, 100744.	3.3	20
719	Integrated analysis of bulk and single-cell RNA sequencing reveals the interaction of PKP1 and tumor-infiltrating B cells and their therapeutic potential for nasopharyngeal carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
720	Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-15.	0.6	0
721	Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. <i>Military Medical Research</i> , 2022, 9, .	1.9	19
722	Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 112-122.	1.9	3
723	Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response. <i>Cancer Research and Treatment</i> , 2023, 55, 671-683.	1.3	3
724	Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
725	The Immune Contexture of Liposarcoma and Its Clinical Implications. <i>Cancers</i> , 2022, 14, 4578.	1.7	6
726	The immune subtypes and landscape of sarcomas. <i>BMC Immunology</i> , 2022, 23, .	0.9	4
727	The soldiers needed to be awakened: Tumor-infiltrating immune cells. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
728	Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2022, 74, 1146-1175.	7.1	8
729	Biomarkers and immunotherapy: where are we?. <i>Current Opinion in Oncology</i> , 2022, 34, 579-586.	1.1	6
730	Intratatumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients. <i>Cancers</i> , 2022, 14, 4298.	1.7	3
731	Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2023, 12, 3068-3078.	1.3	5

#	ARTICLE	IF	CITATIONS
732	Identification of cuproptosis-related subtypes in lung adenocarcinoma and its potential significance. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
733	Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disorders. <i>Anti-Cancer Drugs</i> , 2023, 34, 311-316.	0.7	3
734	Tumour infiltrating B cells discriminate checkpoint blockade-induced responses. <i>European Journal of Cancer</i> , 2022, 177, 164-174.	1.3	3
735	On the road to improved outcomes by capturing leiomyosarcoma patients's™ views. <i>Future Oncology</i> , 0, , .	1.1	1
736	Small round cell sarcomas. <i>Nature Reviews Disease Primers</i> , 2022, 8, .	18.1	9
737	Current Advances in Follicular Regulatory T-cell Biology. <i>Critical Reviews in Immunology</i> , 2022, , .	1.0	0
738	Development and function of tissue-resident memory B cells. <i>Advances in Immunology</i> , 2022, , .	1.1	5
739	Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. , 2022, 10, e003744.		6
740	Immunotherapy for liposarcoma: emerging opportunities and challenges. <i>Future Oncology</i> , 2022, 18, 3449-3461.	1.1	5
741	Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma. <i>Communications Medicine</i> , 2022, 2, .	1.9	6
743	Live or Heat-Killed <i>Lactobacillus rhamnosus</i> Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12748.	1.8	4
744	Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
745	Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed <i>Mycobacterium Obuense</i> (IMM-101) in Patients with Locally Advanced Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 5299.	1.7	1
746	Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
747	Translational Research in Cancer Immunotherapies. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 363-370.	0.0	0
748	Spatial transcriptomics technology in cancer research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	21
749	Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	5
750	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. <i>Cancers</i> , 2022, 14, 4885.	1.7	5

#	ARTICLE	IF	CITATIONS
751	Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 812-822.	1.3	3
752	The immune landscape of undifferentiated pleomorphic sarcoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
753	Expression and prognosis of GNG5 in lower-grade glioma using public database. <i>International Journal of Transgender Health</i> , 2022, 15, 1101-1116.	1.1	0
754	Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. <i>Cells</i> , 2022, 11, 3147.	1.8	3
755	First communication on the efficacy of combined ¹⁷⁷ Lutetium-PSMA with immunotherapy outside prostate cancer. , 2022, 10, e005383.		3
756	Liver Metastasis Modulate Responses of Suppressive Macrophages and Exhausted T Cells to Immunotherapy Revealed by Single Cell Sequencing. <i>Genetics & Genomics Next</i> , 0, , 2200002.	0.8	0
757	Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	11
758	The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy. <i>Cancer Communications</i> , 2022, 42, 1288-1313.	3.7	13
759	Evidence for the Current Management of Soft-tissue Sarcoma and Gastrointestinal Stromal Tumors and Emerging Directions. <i>Surgical Oncology Clinics of North America</i> , 2022, , .	0.6	0
760	Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
761	Human T lymphocytes at tumor sites. <i>Seminars in Immunopathology</i> , 2022, 44, 883-901.	2.8	10
762	Immature and mature antibodies as defenders against cancer. , 0, , .		1
763	Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis. <i>IScience</i> , 2022, 25, 105511.	1.9	2
764	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
765	Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
766	Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting. <i>Cancer Biology and Medicine</i> , 2022, 19, 1496-1502.	1.4	5
769	Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1861-1876.	1.3	4
770	TGF β 2 control of immune responses in cancer: a holistic immuno-oncology perspective. <i>Nature Reviews Immunology</i> , 2023, 23, 346-362.	10.6	23

#	ARTICLE	IF	CITATIONS
792	Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 5968.	1.7	3
793	Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice. , 2022, 10, e005345.		12
794	Identification of B cell marker genes based on single-cell sequencing to establish a prognostic model and identify immune infiltration in osteosarcoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
795	Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors. <i>Disease Markers</i> , 2022, 2022, 1-20.	0.6	6
796	Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. <i>Cells</i> , 2023, 12, 101.	1.8	0
797	Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells. <i>Cancer Research Communications</i> , 2022, 2, 1641-1656.	0.7	2
798	A Combined Risk Score Model to Assess Prognostic Value in Patients with Soft Tissue Sarcomas. <i>Cells</i> , 2022, 11, 4077.	1.8	2
799	Cuproptosis-associated lncRNAs discern prognosis and immune microenvironment in sarcoma victims. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
801	Newly formatted (tertiary) lymphoid structures in tumor growth. <i>Science and Innovations in Medicine</i> , 2022, 7, 269-274.	0.2	0
802	Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1505-1521.	2.0	6
803	3D tumor explant as a novel platform to investigate therapeutic pathways and predictive biomarkers in cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
804	Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. , 2022, 10, e005802.		5
806	Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
807	Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
808	PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 447.	1.7	2
809	Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
810	Exploring the landscape of immunotherapy approaches in sarcomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
811	Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. <i>Epigenomics</i> , 2022, 14, 1449-1464.	1.0	2

#	ARTICLE	IF	CITATIONS
812	Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
813	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
815	Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. <i>Ecancermedicalsecience</i> , 0, 17, .	0.6	1
817	Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers. <i>Laboratory Investigation</i> , 2023, 103, 100063.	1.7	9
818	Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients. <i>International Review of Cell and Molecular Biology</i> , 2023, , 93-116.	1.6	0
820	WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. <i>Cancers</i> , 2023, 15, 393.	1.7	3
821	Exosomal lncRNA HOTAIR induces PDL1+ B cells to impede anti-tumor immunity in colorectal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2023, 644, 112-121.	1.0	7
822	Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas. <i>International Journal of Molecular Sciences</i> , 2023, 24, 680.	1.8	2
823	Biomarkers of tumor-reactive CD4 ⁺ and CD8 ⁺ TILs associate with improved prognosis in endometrial cancer.. , 2022, 10, e005443.		12
824	Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report. <i>Cancer Diagnosis & Prognosis</i> , 2022, 3, 124-129.	0.3	2
825	Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.2	0
827	Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma. <i>Biomolecules</i> , 2023, 13, 58.	1.8	4
828	Role of Noncoding RNAs in the Tumor Immune Microenvironment of Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
829	Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1823-1834.	2.0	6
831	Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
832	Tumor immunology. , 2023, , 245-452.		0
833	Cancer-Associated B Cells in Sarcoma. <i>Cancers</i> , 2023, 15, 622.	1.7	3
834	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
835	Construction of cuproptosis-associated prognostic signature in colon adenocarcinoma based on bioinformatics and RT-qPCR analysis. <i>Oncology Letters</i> , 2023, 25, .	0.8	2
836	Development and Validation of a Machine Learning Model for Detection and Classification of Tertiary Lymphoid Structures in Gastrointestinal Cancers. <i>JAMA Network Open</i> , 2023, 6, e2252553.	2.8	15
837	Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
838	Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2676.	1.8	6
839	B cell-dependent subtypes and treatment-based immune correlates to survival in stage 3 and 4 lung adenocarcinomas. <i>FASEB BioAdvances</i> , 0, , .	1.3	0
840	Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 600.	1.7	3
841	Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. , 2023, 11, e006425.		12
842	Spatial profiling technologies illuminate the tumor microenvironment. <i>Cancer Cell</i> , 2023, 41, 404-420.	7.7	41
843	Current Landscape of Immunotherapy for Advanced Sarcoma. <i>Cancers</i> , 2023, 15, 2287.	1.7	3
844	B cells and tertiary lymphoid structures are associated with survival in papillary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 0, , .	1.8	1
845	Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. <i>Nature Cancer</i> , 2023, 4, 502-515.	5.7	4
846	Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction. <i>Seminars in Cancer Biology</i> , 2023, 91, 50-69.	4.3	10
848	Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer. <i>Frontiers in Artificial Intelligence</i> , 0, 6, .	2.0	0
849	Metabolic dialogs between B cells and the tumor microenvironment: Implications for anticancer immunity. <i>Cancer Letters</i> , 2023, 556, 216076.	3.2	1
850	Next-generation antigen-presenting cell immune therapeutics for gliomas. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	11
851	Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. , 2023, 11, e005545.		10
852	A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma. <i>Current Treatment Options in Oncology</i> , 2023, 24, 212-228.	1.3	1
853	A New Signature of Sarcoma Based on the Tumor Microenvironment Benefits Prognostic Prediction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2961.	1.8	3

#	ARTICLE	IF	CITATIONS
854	IgG4 expression and IgG4/IgG ratio in the tumour invasion front predict long-term outcomes for patients with intrahepatic cholangiocarcinoma. <i>Pathology</i> , 2023, 55, 508-513.	0.3	2
855	The Landscape of Immunotherapy for Retroperitoneal Sarcoma. <i>Current Oncology</i> , 2023, 30, 2144-2158.	0.9	2
856	Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients. <i>Reproductive Sciences</i> , 0, , .	1.1	1
857	High-multiplex tissue imaging in routine pathology“are we there yet?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 801-812.	1.4	5
858	Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells. <i>Acta OncolÃ³gica</i> , 2023, 62, 33-39.	0.8	3
859	Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2023, 11, 546-555.	1.6	2
860	The advent of immune stimulating CAFs in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 258-269.	12.8	22
861	Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. <i>Cancers</i> , 2023, 15, 1282.	1.7	2
862	Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis. <i>Nature Communications</i> , 2023, 14, .	5.8	18
863	Memory Bâ€cell diversity: From early generation to tissue residency and reactivation. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	1
864	High endothelial venules in cancer: Regulation, function, and therapeutic implication. <i>Cancer Cell</i> , 2023, 41, 527-545.	7.7	5
865	Single-cell chemokine receptor profiles delineate the immune contexture of tertiary lymphoid structures in head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2023, 558, 216105.	3.2	3
866	Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors. , 2023, , 1-18.		0
867	New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Research</i> , 2023, 24, .	1.4	2
868	Cancer Initiation and Inflammation. , 2023, , 1-15.		0
870	Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
871	Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma. <i>Cancer Medicine</i> , 2023, 12, 9547-9558.	1.3	2
872	Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab. , 2023, 11, e005848.		1

#	ARTICLE	IF	CITATIONS
873	Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond. <i>Cancers</i> , 2023, 15, 1643.	1.7	1
874	Regulation of CD8 T cell by B-cells: A narrative review. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
875	Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV^{â} HNSCC. <i>Journal of Dental Research</i> , 2023, 102, 678-688.	2.5	4
876	Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. <i>Biomarker Research</i> , 2023, 11, .	2.8	9
877	Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 3166-3169.	0.7	4
878	Emerging Trends in Immunotherapy for Adult Sarcomas. <i>Oncologist</i> , 0, , .	1.9	2
879	B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. <i>Cancer Cell</i> , 2023, 41, 466-489.	7.7	16
880	B cell-related tertiary lymphoid structure may exert inhibitory effects on lung adenocarcinoma and SARS-COV-2. <i>Heliyon</i> , 2023, 9, e14334.	1.4	0
881	Functional precision oncology using patient-derived assays: bridging genotype and phenotype. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 305-317.	12.5	18
883	Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. <i>Nature Medicine</i> , 2023, 29, 593-604.	15.2	46
885	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
886	Application and Prospect between m6A and LncRNA in Pancreatic Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 3883-3888.	0.0	0
887	Towards a consensus definition of immune exclusion in cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
889	Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice. <i>Nature Communications</i> , 2023, 14, .	5.8	9
890	The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
891	Response Evaluation of Neoadjuvant Therapies in Sarcoma. <i>Current Treatment Options in Oncology</i> , 0, , .	1.3	0
892	Targeting the Molecular and Immunologic Features of Leiomyosarcoma. <i>Cancers</i> , 2023, 15, 2099.	1.7	5
893	Microenvironmental Changes in Mediastinal Fat-associated Lymphoid Clusters and Lungs in Early and Late Stages of Metastatic Lung Cancer Induction. <i>Microscopy and Microanalysis</i> , 2023, 29, 1228-1243.	0.2	2

#	ARTICLE	IF	CITATIONS
895	Tumor immune microenvironment of cutaneous angiosarcoma with cancer testis antigens and the formation of tertiary lymphoid structures. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
897	Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2023, 128, 2175-2185.	2.9	9
898	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. <i>Human Genomics</i> , 2023, 17, .	1.4	1
899	Emerging predictive biomarkers in the management of bone and soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	1
900	Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
901	Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment. <i>Cancers</i> , 2023, 15, 2182.	1.7	2
902	Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer. <i>PeerJ</i> , 0, 11, e15088.	0.9	0
903	The roles of tertiary lymphoid structures in chronic diseases. <i>Nature Reviews Nephrology</i> , 2023, 19, 525-537.	4.1	24
904	Immune checkpoint therapyâ€”current perspectives and future directions. <i>Cell</i> , 2023, 186, 1652-1669.	13.5	114
905	T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in <i>Schistosoma haematobium</i> associated bladder cancer: First report from Upper Egypt. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011258.	1.3	2
906	Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. <i>Cancer Letters</i> , 2023, 562, 216182.	3.2	15
907	Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	11
908	Deciphering the maturation of tertiary lymphoid structures in cancer and inflammatory diseases of the digestive tract using imaging mass cytometry. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
909	CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma. <i>Nature Cancer</i> , 2023, 4, 665-681.	5.7	12
928	Localization, tissue biology and T cell state â€” implications for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2023, 23, 807-823.	10.6	10
945	T cells in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	36
964	Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers. , 2023, 20, 1040-1050.		2
969	The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. <i>British Journal of Cancer</i> , 2023, 129, 1041-1049.	2.9	4

#	ARTICLE	IF	CITATIONS
971	Local Onco-Sphere: Tumor-Immune Cells Interactions. , 2023, , 51-76.		0
993	Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	7
1000	è,žç~ç,ã...³çš,,ã,%oç°\$æ·â·ç»“æž,,çš,,æf€æµ«â³Œé†âŒE-â^†æž• Journal of Zhejiang University: Science B, 2023, 24, 779-795. 1		1
1006	Exploiting Exosomes for Cancer Diagnosis and Treatment. Current Cancer Research, 2023, , 43-59.	0.2	0
1008	The effect of physical exercise on anticancer immunity. Nature Reviews Immunology, 0, , .	10.6	3
1014	Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application. Journal of Cancer Research and Clinical Oncology, 2023, 149, 17635-17649.	1.2	1
1053	Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46.	12.5	1
1060	B Cells and Antibody Production in Cancer. , 2024, , 1-20.		0
1061	How chemokines organize the tumour microenvironment. Nature Reviews Cancer, 2024, 24, 28-50.	12.8	0
1067	How B cells drive T-cell responses: A key role for cross-presentation of antibody-targeted antigens. Advances in Immunology, 2023, , 37-57.	1.1	0
1085	Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology. Nature Biotechnology, 0, , .	9.4	2
1117	Cationic polymer-based nanoparticles in cancer vaccines. , 2024, , 401-429.		0